News
Latest News
Our Q3 2024 newsletter focusses on metabolism of degraders, gut metabolites, qNMR, as well as our latest blog articles and paper picks.
Our Q2 2024 newsletter focusses on UGT1A4 mediated N-glucuronidation of drugs and how to access these metabolites.
Our Q4 2023 newsletter looks at Hypha’s new late-stage oxidation and deoxyfluorination techniques for blocking metabolic soft spots.
Major O-demethylated human metabolites of ivermectin that reduce Anopheles survival were made by Hypha’s microbial biotransformation system, and are the focus feature of our Q3 2023 newsletter.
Our Q2 2023 newsletter focusses on synthesis of acyl glucuronides, hydroxylated metabolites and our latest blogs
Metabolites of the FDA approved anti-fungal drug rezafungin were made by Hypha’s microbial biotransformation system.
Our Q1 2023 newsletter focusses on Hypha’s recombinant enzymes, in particular innovations to the PolyCYPs platform.
Our Q4 2022 newsletter focusses on synthesis of deuterated metabolites with case studies to illustrate biotransformation and chemical routes.
Hypha’s Q3 2022 newsletter highlights our new gut metabolites service and a case study featuring the production of amino acid conjugates by microbial biotransformation.
Hypha’s Q2 2022 newsletter features synthesis of GSH conjugates using PolyCYPs enzymes, metabolite purification case studies, and information on our late-stage oxidation kits.
Hypha’s new service for accessing API degradation products and impurities is featured in our Q1 2022 newsletter. Also highlighted is the CYP active site engineering our Recombinant Technologies Team have undertaken to further develop PolyCYPs enzymes.
In our Q4 2021 technical newsletter we describe how Hypha used PolyCYPs to help the Open Source Antibiotics team identify a drug metabolite.
Stay up to date with the latest news from Hypha Discovery
Sign up for our quarterly newsletters and monthly "Metabolite Tales" blog
Ready to begin? Our scientists are available to talk through your requirements
Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.